Zacks: Analysts Anticipate Agenus Inc. (AGEN) to Post -$0.37 Earnings Per Share

Equities analysts expect that Agenus Inc. (NASDAQ:AGEN) will post earnings of ($0.37) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Agenus’ earnings. Agenus reported earnings per share of ($0.30) in the same quarter last year, which would suggest a negative year over year growth rate of 23.3%. The firm is scheduled to issue its next earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Agenus will report full-year earnings of ($1.19) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.12). For the next year, analysts anticipate that the company will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.40) to ($1.37). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Agenus.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.37). The company had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $5.91 million. The business’s quarterly revenue was down 24.4% on a year-over-year basis.

Several equities research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Agenus from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. Zacks Investment Research upgraded shares of Agenus from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research note on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. Agenus has an average rating of “Hold” and a consensus price target of $5.81.

Shares of Agenus (NASDAQ AGEN) traded down $0.07 during mid-day trading on Friday, hitting $3.77. 982,700 shares of the stock traded hands, compared to its average volume of 1,190,596. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of -2.39. Agenus has a 12 month low of $3.20 and a 12 month high of $5.45.

In other Agenus news, CEO Garo H. Armen acquired 100,000 shares of Agenus stock in a transaction that occurred on Monday, October 30th. The stock was acquired at an average cost of $3.55 per share, for a total transaction of $355,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 7.90% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in AGEN. Vanguard Group Inc. grew its position in shares of Agenus by 5.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock valued at $13,805,000 after purchasing an additional 174,162 shares in the last quarter. Artal Group S.A. grew its position in shares of Agenus by 25.0% during the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after purchasing an additional 500,000 shares in the last quarter. Northern Trust Corp grew its position in shares of Agenus by 4.1% during the 2nd quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock valued at $3,682,000 after purchasing an additional 37,239 shares in the last quarter. Candriam Luxembourg S.C.A. grew its position in shares of Agenus by 12.8% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 617,700 shares of the biotechnology company’s stock valued at $2,724,000 after purchasing an additional 70,000 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Agenus by 5.8% during the 1st quarter. Geode Capital Management LLC now owns 554,572 shares of the biotechnology company’s stock valued at $2,090,000 after purchasing an additional 30,265 shares in the last quarter. Institutional investors and hedge funds own 37.90% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/12/06/zacks-analysts-anticipate-agenus-inc-agen-to-post-0-37-earnings-per-share.html.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get a free copy of the Zacks research report on Agenus (AGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply